Rebamipide suppresses TNF-[alpha] mediated inflammation in vitro and attenuates the severity of dermatitis in mice

Rebamipide is a routine drug for the treatment of gastritis in a clinical setting. Recently, it has been shown to protect against various inflammatory diseases, and has provided a potential therapy for these diseases. However, whether rebamipide has a role in dermatitis remains to be elucidated. Her...

Full description

Saved in:
Bibliographic Details
Published in:The FEBS journal 2015-06, Vol.282 (12), p.2317
Main Authors: Li, Weiwei, Zhao, Yunpeng, Xu, Xiangling, Ma, Weiyuan, Gao, Peng, Wang, Yan, Liang, Ke, Li, Ruifeng
Format: Article
Language:English
Subjects:
Dermatitis
Drug therapy
Pharmacology
Rodents
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rebamipide is a routine drug for the treatment of gastritis in a clinical setting. Recently, it has been shown to protect against various inflammatory diseases, and has provided a potential therapy for these diseases. However, whether rebamipide has a role in dermatitis remains to be elucidated. Here, we found that rebamipide alleviated the inflammatory reaction induced by tumor necrosis factor-[alpha] in RAW264.7, a stable macrophage cell line. Furthermore, rebamipide treatment repressed activation of nuclear factor-kappaB signaling, a well-established inflammatory signaling pathway. Moreover, an oxazolone-induced dermatitis mouse model was established to investigate the role of rebamipide in vivo. PBS control group exhibited typical skin inflammation, whereas treatment with rebamipide remarkably attenuated a dermatitis phenotype in this mouse model. The protective role of rebamipide in dermatitis in vivo was probably due to its inhibition of nuclear factor-kappaB signaling. Collectively, rebamipide may represent a promising molecular target for the prevention and treatment of inflammatory skin diseases.
ISSN:1742-464X
1742-4658
DOI:10.1111/febs.13278